Premium
Proteomic characterization of freeze‐dried human plasma: providing treatment of bleeding disorders without the need for a cold chain
Author(s) -
Steil Leif,
Thiele Thomas,
Hammer Elke,
Bux Jürgen,
Kalus Monika,
Völker Uwe,
Greinacher Andreas
Publication year - 2008
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2008.01856.x
Subject(s) - proteome , clotting factor , chemistry , blood proteins , fresh frozen plasma , human plasma , freeze drying , cold chain , chromatography , biochemistry , medicine , platelet , food science , immunology
BACKGROUND: Transfusion of human plasma is a basic treatment for severe coagulopathies, especially in major bleeding. The required logistics to provide plasma is challenging because of the need to maintain a cold chain. This disadvantage could be overcome by lyophilized plasma. However, it is unknown to what extent lyophilization alters plasma proteins. Quantitative proteomic technologies were applied to monitor protein changes during production of lyophilized, solvent/detergent (S/D)‐treated plasma. MATERIALS AND METHODS: The impact of S/D treatment and lyophilization on the plasma proteome was evaluated by differential in‐gel electrophoresis (2D‐DIGE), and proteins were characterized by mass spectrometry. Clotting factor activities were determined in lyophilized S/D‐treated plasma after 24 months of storage at room temperature. RESULTS: By 2D‐DIGE, 600 individual protein spots were compared. Lyophilization did not change any of the 600 spots, whereas pathogen inactivation caused significant changes of 38 spots including α1‐antitrypsin, α1‐antichymotrypsin, and α2‐antiplasmin. Clotting factor activities remained stable over 24 months of storage. CONCLUSION: Lyophilization of human plasma neither alters its protein composition nor impairs its clotting capacity. It does not require cost‐intensive logistics for storage and transport and can be quickly reconstituted. It is suggested that lyophilized, pathogen‐inactivated plasma is an attractive option to provide the most important basic treatment for severe coagulopathies in areas without cold chain and to provide plasma with reduced time delay in emergency situations.